Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health Specialties

Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial

A 12-week randomized trial demonstrates that combining metformin and nanocurcumin significantly improves lipid metabolism, glucose regulation, hormonal balance, and body metrics in women with PCOS, surpassing effects seen with either agent alone or placebo.
Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial
Posted inClinical Updates OB/GYN & Women's Health Oncology Specialties

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

This phase II study shows that adding metformin to standard chemoradiotherapy in locally advanced cervical cancer is safe, well tolerated, and feasible, with no significant increase in severe adverse events and successful biomarker-based tumor hypoxia assessments.
Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial
Posted inOB/GYN & Women's Health Oncology Specialties

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.
Vitamin D3 as a Potential Therapeutic Agent in Polycystic Ovary Syndrome: Insights from a Prospective Double-Blind Randomized Trial
Posted inClinical Updates Family Medicine & Nutrition news OB/GYN & Women's Health Specialties

Vitamin D3 as a Potential Therapeutic Agent in Polycystic Ovary Syndrome: Insights from a Prospective Double-Blind Randomized Trial

A recent double-blind randomized controlled trial demonstrates that weekly supplementation with vitamin D3 significantly improves ovarian morphology, menstrual regularity, and ovulation rates in women with PCOS, suggesting a role as standalone or adjunctive therapy.
EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation
Posted inClinical Updates news OB/GYN & Women's Health Oncology

EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation

The phase III EPIK-O trial showed no progression-free survival benefit of alpelisib plus olaparib over chemotherapy in BRCA wild-type platinum-resistant or refractory high-grade serous ovarian cancer, highlighting treatment challenges and biomarker insights.
Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review
Posted inClinical Updates news OB/GYN & Women's Health Specialties

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.
Targeted Reduction of Sitting Time Versus Increased Sit-to-Stand Transitions: Effects on Blood Pressure and Glucose Regulation in Postmenopausal Women
Posted inCardiology Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news OB/GYN & Women's Health Specialties

Targeted Reduction of Sitting Time Versus Increased Sit-to-Stand Transitions: Effects on Blood Pressure and Glucose Regulation in Postmenopausal Women

A 3-month randomized trial in overweight postmenopausal women found that increasing sit-to-stand transitions significantly reduces diastolic blood pressure, while reducing total sitting time alone does not improve blood pressure or glucoregulatory measures.
Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial
Posted inClinical Updates news OB/GYN & Women's Health Oncology Specialties

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial

The ICARUS-BREAST01 phase 2 trial demonstrated patritumab deruxtecan's efficacy and manageable safety in HR+HER2− metastatic breast cancer post-CDK4/6 inhibitors, highlighting key biomarkers linked to response and resistance.